Gaksch Martin, Jorde Rolf, Grimnes Guri, Joakimsen Ragnar, Schirmer Henrik, Wilsgaard Tom, Mathiesen Ellisiv B, Njølstad Inger, Løchen Maja-Lisa, März Winfried, Kleber Marcus E, Tomaschitz Andreas, Grübler Martin, Eiriksdottir Gudny, Gudmundsson Elias F, Harris Tamara B, Cotch Mary F, Aspelund Thor, Gudnason Vilmundur, Rutters Femke, Beulens Joline W J, van 't Riet Esther, Nijpels Giel, Dekker Jacqueline M, Grove-Laugesen Diana, Rejnmark Lars, Busch Markus A, Mensink Gert B M, Scheidt-Nave Christa, Thamm Michael, Swart Karin M A, Brouwer Ingeborg A, Lips Paul, van Schoor Natasja M, Sempos Christopher T, Durazo-Arvizu Ramón A, Škrabáková Zuzana, Dowling Kirsten G, Cashman Kevin D, Kiely Mairead, Pilz Stefan
Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
Tromsø Endocrine Research Group, Department of Clinical Medicine, University of Tromsø, Tromsø, Norway.
PLoS One. 2017 Feb 16;12(2):e0170791. doi: 10.1371/journal.pone.0170791. eCollection 2017.
Vitamin D deficiency may be a risk factor for mortality but previous meta-analyses lacked standardization of laboratory methods for 25-hydroxyvitamin D (25[OH]D) concentrations and used aggregate data instead of individual participant data (IPD). We therefore performed an IPD meta-analysis on the association between standardized serum 25(OH)D and mortality.
In a European consortium of eight prospective studies, including seven general population cohorts, we used the Vitamin D Standardization Program (VDSP) protocols to standardize 25(OH)D data. Meta-analyses using a one step procedure on IPD were performed to study associations of 25(OH)D with all-cause mortality as the primary outcome, and with cardiovascular and cancer mortality as secondary outcomes. This meta-analysis is registered at ClinicalTrials.gov, number NCT02438488.
We analysed 26916 study participants (median age 61.6 years, 58% females) with a median 25(OH)D concentration of 53.8 nmol/L. During a median follow-up time of 10.5 years, 6802 persons died. Compared to participants with 25(OH)D concentrations of 75 to 99.99 nmol/L, the adjusted hazard ratios (with 95% confidence interval) for mortality in the 25(OH)D groups with 40 to 49.99, 30 to 39.99, and <30 nmol/L were 1.15 (1.00-1.29), 1.33 (1.16-1.51), and 1.67 (1.44-1.89), respectively. We observed similar results for cardiovascular mortality, but there was no significant linear association between 25(OH)D and cancer mortality. There was also no significantly increased mortality risk at high 25(OH)D levels up to 125 nmol/L.
In the first IPD meta-analysis using standardized measurements of 25(OH)D we observed an association between low 25(OH)D and increased risk of all-cause mortality. It is of public health interest to evaluate whether treatment of vitamin D deficiency prevents premature deaths.
维生素D缺乏可能是死亡的一个风险因素,但既往的荟萃分析缺乏对25-羟基维生素D(25[OH]D)浓度实验室检测方法的标准化,且使用的是汇总数据而非个体参与者数据(IPD)。因此,我们对标准化血清25(OH)D与死亡率之间的关联进行了一项IPD荟萃分析。
在一个由八项前瞻性研究组成的欧洲联盟中,包括七个人群队列,我们使用维生素D标准化计划(VDSP)方案对25(OH)D数据进行标准化。采用一步法对IPD进行荟萃分析,以研究25(OH)D与全因死亡率(作为主要结局)以及心血管和癌症死亡率(作为次要结局)之间的关联。这项荟萃分析已在ClinicalTrials.gov注册,注册号为NCT02438488。
我们分析了26916名研究参与者(年龄中位数61.6岁,女性占58%),25(OH)D浓度中位数为53.8 nmol/L。在中位随访时间10.5年期间,6802人死亡。与25(OH)D浓度为75至99.99 nmol/L的参与者相比,25(OH)D浓度为40至49.99、30至39.99以及<30 nmol/L组的死亡率调整后风险比(及其95%置信区间)分别为1.15(1.00 - 1.29)、1.33(1.16 - 1.51)和1.67(1.44 - 1.89)。我们观察到心血管死亡率有类似结果,但25(OH)D与癌症死亡率之间无显著线性关联。在25(OH)D水平高达125 nmol/L时,死亡风险也没有显著增加。
在首次使用标准化25(OH)D测量的IPD荟萃分析中,我们观察到低25(OH)D与全因死亡率风险增加之间存在关联。评估维生素D缺乏的治疗是否能预防过早死亡具有公共卫生意义。